$ABBV · AbbVie Inc.
AbbVie filed an 8-K disclosing that Q3 2026 GAAP and adjusted earnings will include a $216 million pre-tax acquired IPR&D and milestones expense, representing a $0.11 per-share headwind. The company revised its Q3 adjusted EPS guidance to $3.73–$3.77 (from $3.84–$3.88 ex-IPR&D) and full-year 2026 adjusted EPS guidance to $13.76–$13.96 (from $13.87–$14.07). Results remain preliminary pending financial statement close.
- Q3 2026 acquired IPR&D and milestones expense of $216M pre-tax, a $0.11 hit to both GAAP and adjusted EPS.
- Q3 adjusted EPS guidance revised to $3.73–$3.77, down from prior $3.84–$3.88 (ex-IPR&D).
- Full-year 2026 adjusted EPS guidance trimmed to $13.76–$13.96, down from $13.87–$14.07.
- AbbVie does not forecast acquired IPR&D/milestones expense; further charges beyond Q3 2026 are possible.
- Results for the quarter ended September 30, 2026 are not yet finalized and remain subject to closing procedures.
Extended-hours trading shows ABBV at $265.00, down 0.29% from the regular close of $265.76 — a muted reaction consistent with the modest $0.11 guidance trim on a $469.54B market-cap name.
The guidance trim is small but notable because AbbVie explicitly excludes future IPR&D charges from its forecast, meaning additional unplanned hits are possible before year-end.
Large-cap pharma peers routinely exclude acquired IPR&D from guidance due to unpredictability; AbbVie's $216M charge is modest relative to its ~$56B annual revenue base and does not signal operational weakness.
Q3 results are preliminary and subject to financial statement closing procedures; final results could differ. Additional IPR&D and milestones expense beyond Q3 2026 is not included in guidance and cannot be reliably forecasted.
Get filings like this before the market reacts.
Real-time SEC filing alerts, AI summaries, and a free daily digest — plus portfolio tracking that ties filings to your positions.